sildenafil-citrate has been researched along with Venous-Thrombosis* in 4 studies
4 other study(ies) available for sildenafil-citrate and Venous-Thrombosis
Article | Year |
---|---|
Deep vein thrombosis associated with sildenafil.
Topics: Aged; Femoral Vein; Humans; Male; Saphenous Vein; Sildenafil Citrate; Urological Agents; Venous Thrombosis | 2019 |
Sildenafil related cerebral venous thrombosis following spinal anesthesia.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Local; Angiography, Digital Subtraction; Cerebral Angiography; Cerebral Veins; Elective Surgical Procedures; Erectile Dysfunction; Fibrinolytic Agents; Hernia, Inguinal; Herniorrhaphy; Humans; Intracranial Thrombosis; Male; Phosphodiesterase 5 Inhibitors; Post-Dural Puncture Headache; Sildenafil Citrate; Tomography, X-Ray Computed; Urological Agents; Venous Thrombosis | 2017 |
Venous leakage treatment revisited: pelvic venoablation using aethoxysclerol under air block technique and Valsalva maneuver.
We evaluated the effectiveness of pelvic vein embolization with aethoxysclerol in aero-block technique for the treatment of impotence due to venous leakage in men using sildenafil for intercourse. The aim of the procedure was to reduce the use of sildenafil.. A total of 96 patients with veno-occlusive dysfunction, severe enough for the need of PDE5 inhibitors for vaginal penetration, underwent pelvic venoablation with aethoxysclerol. The mean patient age was 53.5 years. Venous leaks were identified by Color Doppler Ultrasound after intracavernous alprostadil injection. Under local anesthesia a 20-gauge needle was inserted into the deep dorsal penile vein. The pelvic venogram was obtained through deep dorsal venography. Aethoxysclerol 3% as sclerosing agent was injected after air-block under Valsalva manoeuver. Success was defined as the ability to achieve vaginal insertion without the aid of any drugs, vasoactive injections, penile prosthesis, or vacuum device. Additionally, a pre- and post- therapy IIEF score and a digital overnight spontaneous erections protocol (OSEP) with the NEVA™-system was performed.. At 3 month follow-up 77 out of 96 patients (80.21%) reported to have erections sufficient for vaginal insertion without the use of any drug or additional device. Four (4.17%) patients did not report any improvement. Follow up with color Doppler ultrasound revealed a new or persistent venous leakage in 8 (8.33%) of the patients. No serious complications occurred.. Our new pelvic venoablation technique using aethoxysclerol in air-block technique was effective, minimally invasive, and cost-effective. All patients were able to perform sexual intercourse without the previously used dosage of PDE5 inhibitor. This new method may help in patients with contra-indications against PDE5 inhibitors, in patients who cannot afford the frequent usage of expensive oral medication or those who do not fully respond to PDE5-inhibitors. Topics: Adult; Aged; Air; Austria; Contraindications; Cost-Benefit Analysis; Follow-Up Studies; Humans; Impotence, Vasculogenic; Italy; Male; Middle Aged; Penile Erection; Penis; Phlebography; Phosphodiesterase 5 Inhibitors; Piperazines; Polidocanol; Polyethylene Glycols; Purines; Quality of Life; Sclerosing Solutions; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Ultrasonography, Doppler, Color; Valsalva Maneuver; Venous Thrombosis | 2015 |
Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction.
Acquired or hereditary prothrombotic risk factors may lead to cerebral venous sinus thrombosis (CVST), particularly when other predisposing factors coexist. A 57-year-old man experienced right leg deep venous thrombosis, severe thrombosis of the haemorrhoid plexus and CVST over a 12-month period during which he was taking sildenafil regularly twice a week. Sildenafil is a phosphodiesterase 5 (PDE5)-inhibitor used for erectile dysfunction (ED). A slight reduction in antithrombin III and free protein S levels was demonstrated. After suspension of sildenafil and six months on oral anticoagulants, clinical improvement was obtained. Recurrent venous thrombosis, including CVST, may complicate prolonged treatment with PDE5-inhibitors in subjects at risk. Periodic monitoring of clotting factors is recommended in these subjects. Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; Chronic Disease; Cranial Sinuses; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Secondary Prevention; Sildenafil Citrate; Sinus Thrombosis, Intracranial; Sulfones; Treatment Outcome; Venous Thrombosis | 2007 |